Teladoc Health Key Executives
This section highlights Teladoc Health's key executives, including their titles and compensation details.
Find Contacts at Teladoc Health
(Showing 0 of )
Teladoc Health Earnings
This section highlights Teladoc Health's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Date:
April 30, 2025
Time:
After Market
Est. EPS:
$-0.33
Status:
Unconfirmed
Last Earnings Results
Date:
February 26, 2025
EPS:
$-0.28
Est. EPS:
$-0.21
Revenue:
$640.49M
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-26 | $-0.21 | $-0.28 |
| Read Transcript | Q3 | 2024 | 2024-10-30 | $-0.29 | $-0.19 |
| Read Transcript | Q2 | 2024 | 2024-07-31 | $-0.36 | $-0.28 |
| Read Transcript | Q1 | 2024 | 2024-04-25 | $-0.47 | $-0.49 |
| Read Transcript | Q4 | 2023 | 2024-02-20 | $-0.22 | $-0.17 |
| Read Transcript | Q3 | 2023 | 2023-10-24 | $-0.37 | $-0.35 |
| Read Transcript | Q2 | 2023 | 2023-07-25 | $-0.44 | $-0.40 |
| Read Transcript | Q1 | 2023 | 2023-04-28 | N/A | N/A |
Teladoc Health, Inc. provides virtual healthcare services in the United States and internationally. The company offers a portfolio of services and solutions covering non-urgent, episodic, chronic, and complicated medical conditions, including diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and mental health conditions. It offers a range of programs and services, including primary and specialty care telehealth solutions, chronic condition management, expert medical services, mental health solutions, and platform and program services. The company serves employers, health plans, hospitals and health systems, and insurance and financial services companies, as well as individual members. It offers its products and services under the Teladoc, Livongo, and BetterHelp brands. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. The company was incorporated in 2002 and is headquartered in Purchase, New York.
Healthcare
Medical - Healthcare Information Services
$7.16
Stock Price
$1.25B
Market Cap
5.50K
Employees
Purchase, NY
Location
Financial Statements
Access annual & quarterly financial statements for Teladoc Health, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $2.57B | $2.60B | $2.41B | $2.03B | $1.09B |
| Cost of Revenue | $751.27M | $760.03M | $743.99M | $650.26M | $390.83M |
| Gross Profit | $1.82B | $1.84B | $1.66B | $1.38B | $703.13M |
| Gross Profit Ratio | 70.76% | 70.80% | 69.09% | 68.01% | 64.27% |
| Research and Development Expenses | $307.27M | $348.52M | $333.63M | $311.88M | $164.94M |
| General and Administrative Expenses | $435.49M | $464.66M | $449.86M | $438.01M | $506.68M |
| Selling and Marketing Expenses | $705.79M | $902.63M | $850.71M | $667.31M | $380.20M |
| Selling General and Administrative Expenses | $1.14B | $1.37B | $1.30B | $1.11B | $886.88M |
| Other Expenses | $1.39B | $375.12M | $256.03M | $204.24M | $69.50M |
| Operating Expenses | $2.84B | $2.09B | $1.89B | $1.62B | $1.12B |
| Cost and Expenses | $3.59B | $2.85B | $2.63B | $2.27B | $1.51B |
| Interest Income | $57.07M | $46.78M | $9.27M | $80.36M | $59.95M |
| Interest Expense | $23.80M | $22.28M | $9.27M | $80.36M | $60.49M |
| Depreciation and Amortization | $382.84M | $351.32M | $270.64M | $219.62M | $78.09M |
| EBITDA | $-587.01M | $154.00M | $-13.38B | $-84.67M | $-438.01M |
| EBITDA Ratio | -22.84% | 5.92% | -556.06% | -4.17% | -40.04% |
| Operating Income | $-1.02B | $-248.55M | $13.20B | $-238.99M | $-418.19M |
| Operating Income Ratio | -39.73% | -9.55% | 548.37% | -11.76% | -38.23% |
| Total Other Income Expenses Net | $27.23M | $28.95M | $-10.13M | $-119.03M | $-69.57M |
| Income Before Tax | $-993.65M | $-219.61M | $-13.66B | $-384.66M | $-575.99M |
| Income Before Tax Ratio | -38.67% | -8.44% | -567.69% | -18.92% | -52.65% |
| Income Tax Expense | $7.59M | $760.00K | $-3.81M | $44.14M | $-90.86M |
| Net Income | $-1.00B | $-220.37M | $-13.66B | $-428.79M | $-485.14M |
| Net Income Ratio | -38.97% | -8.47% | -567.53% | -21.09% | -44.35% |
| EPS | $-5.87 | $-1.36 | $-84.60 | $-2.73 | $-5.36 |
| EPS Diluted | $-5.87 | $-1.34 | $-84.60 | $-2.73 | $-5.36 |
| Weighted Average Shares Outstanding | 170.56M | 162.17M | 161.46M | 156.94M | 90.51M |
| Weighted Average Shares Outstanding Diluted | 170.56M | 164.58M | 161.46M | 156.94M | 90.51M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $640.49M | $640.51M | $642.44M | $646.13M | $660.53M | $660.24M | $652.41M | $629.24M | $637.71M | $611.40M | $592.38M | $565.35M | $554.24M | $521.66M | $503.14M | $453.68M | $383.32M | $288.81M | $241.03M | $180.80M |
| Cost of Revenue | $188.93M | $179.75M | $284.62M | $292.43M | $193.42M | $185.96M | $190.54M | $190.11M | $188.87M | $185.62M | $182.47M | $187.03M | $174.99M | $169.04M | $160.27M | $145.96M | $122.94M | $104.72M | $90.78M | $72.38M |
| Gross Profit | $451.56M | $460.76M | $357.82M | $353.70M | $467.10M | $474.28M | $461.87M | $439.14M | $448.84M | $425.78M | $409.91M | $378.32M | $379.25M | $352.62M | $342.87M | $307.72M | $260.38M | $184.09M | $150.25M | $108.42M |
| Gross Profit Ratio | 70.50% | 71.94% | 55.70% | 54.74% | 70.72% | 71.83% | 70.79% | 69.79% | 70.38% | 69.64% | 69.20% | 66.92% | 68.43% | 67.60% | 68.15% | 67.83% | 67.93% | 63.74% | 62.34% | 59.97% |
| Research and Development Expenses | $76.75M | $72.38M | $76.75M | $81.39M | $89.94M | $84.29M | $87.31M | $86.98M | $82.93M | $87.81M | $80.83M | $87.41M | $72.87M | $80.25M | $80.76M | $78.01M | $92.70M | $29.96M | $23.03M | $19.26M |
| General and Administrative Expenses | $100.00M | $114.25M | $109.55M | $111.70M | $95.08M | $115.72M | $139.71M | $114.14M | $119.84M | $112.54M | $110.87M | $104.92M | $118.60M | $103.02M | $111.22M | $105.17M | $343.99M | $59.74M | $56.62M | $46.34M |
| Selling and Marketing Expenses | $174.73M | $224.93M | $220.71M | $237.69M | $53.01M | $186.15M | $218.41M | $231.28M | $202.72M | $233.55M | $222.50M | $191.93M | $172.32M | $173.68M | $167.08M | $154.23M | $187.69M | $75.78M | $66.27M | $50.45M |
| Selling General and Administrative Expenses | $274.72M | $339.17M | $330.26M | $349.39M | $148.09M | $301.87M | $358.13M | $345.43M | $322.57M | $346.10M | $333.37M | $296.85M | $290.92M | $276.70M | $278.29M | $259.40M | $531.68M | $135.53M | $122.88M | $96.80M |
| Other Expenses | $148.30M | $93.61M | $-563.00K | $-370.00K | $-143.46M | $-1.79M | $75.47M | $69.78M | $75.72M | $62.01M | $59.37M | $58.93M | $52.33M | $51.91M | $51.34M | $48.66M | $36.96M | $12.93M | $9.89M | $9.71M |
| Operating Expenses | $499.78M | $505.16M | $407.01M | $430.78M | $238.03M | $386.16M | $520.90M | $502.19M | $481.21M | $495.92M | $473.57M | $443.20M | $416.12M | $408.85M | $410.39M | $386.07M | $661.34M | $178.42M | $155.80M | $125.76M |
| Cost and Expenses | $688.71M | $684.91M | $691.63M | $723.21M | $431.45M | $572.12M | $711.44M | $692.30M | $670.09M | $681.54M | $656.04M | $630.22M | $591.11M | $577.89M | $570.67M | $532.03M | $784.28M | $283.14M | $246.58M | $198.15M |
| Interest Income | $14.23M | $15.33M | $13.57M | $13.94M | $13.71M | $12.61M | $11.56M | $3.65M | $1.89M | $4.80M | $1.23M | $- | $- | $- | $- | $- | $- | $252.00K | $- | $685.00K |
| Interest Expense | $6.85M | $5.66M | $5.65M | $5.65M | $14.45M | $5.65M | $5.83M | $5.26M | $- | $1.35M | $4.34M | $5.48M | $18.87M | $18.89M | $20.47M | $22.12M | $20.82M | $17.22M | $13.26M | $9.30M |
| Depreciation and Amortization | $91.67M | $91.81M | $98.85M | $100.50M | $101.48M | $97.49M | $79.51M | $73.52M | $78.88M | $65.43M | $63.45M | $62.88M | $57.03M | $55.07M | $55.91M | $50.37M | $40.06M | $15.37M | $11.43M | $11.23M |
| EBITDA | $50.35M | $64.98M | $-729.29M | $26.95M | $81.65M | $40.39M | $15.17M | $4.97M | $-3.73B | $-3.06M | $-3.03B | $-11.87M | $15.18M | $-6.73M | $-54.24M | $-41.83M | $-421.64M | $-5.58M | $-3.39M | $-11.30M |
| EBITDA Ratio | 7.86% | 10.14% | -113.52% | 4.17% | 12.36% | 6.12% | 2.33% | 0.79% | -585.38% | -0.50% | -512.32% | -2.10% | 2.74% | -1.29% | -10.78% | -9.22% | -110.00% | -1.93% | -1.41% | -6.25% |
| Operating Income | $-48.22M | $-44.40M | $-49.19M | $-77.08M | $-87.13M | $-64.72M | $-47.68M | $-49.01M | $3.75B | $-70.14M | $-63.66M | $-64.87M | $-37.27M | $-60.58M | $-78.95M | $-84.68M | $-458.51M | $-19.73M | $-7.18M | $-21.01M |
| Operating Income Ratio | -7.53% | -6.93% | -7.66% | -11.93% | -13.19% | -9.80% | -7.31% | -7.79% | 588.17% | -11.47% | -10.75% | -11.47% | -6.73% | -11.61% | -15.69% | -18.66% | -119.61% | -6.83% | -2.98% | -11.62% |
| Total Other Income Expenses Net | $44.00K | $11.90M | $7.36M | $7.92M | $9.71M | $5.17M | $5.52M | $8.55M | $3.64M | $-2.92M | $-6.10M | $-4.76M | $-19.30M | $-20.12M | $-51.67M | $-27.93M | $-20.92M | $-18.45M | $-20.90M | $-9.30M |
| Income Before Tax | $-48.17M | $-32.50M | $-833.79M | $-79.20M | $-25.38M | $-59.56M | $-66.13M | $-68.55M | $-3.81B | $-74.65M | $-3.10B | $-6.67B | $-60.73M | $-80.70M | $-130.62M | $-112.61M | $-479.42M | $-38.17M | $-28.08M | $-30.31M |
| Income Before Tax Ratio | -7.52% | -5.07% | -129.78% | -12.26% | -3.84% | -9.02% | -10.14% | -10.89% | -597.75% | -12.21% | -523.76% | -1180.53% | -10.96% | -15.47% | -25.96% | -24.82% | -125.07% | -13.22% | -11.65% | -16.77% |
| Income Tax Expense | $238.00K | $780.00K | $3.88M | $2.69M | $3.52M | $-2.48M | $-952.00K | $681.00K | $-1.84M | $-1.17M | $-1.19M | $388.00K | $-49.74M | $3.64M | $3.20M | $87.04M | $-85.46M | $-2.29M | $-2.40M | $-711.00K |
| Net Income | $-48.41M | $-33.28M | $-837.67M | $-81.89M | $-28.89M | $-57.07M | $-65.18M | $-69.23M | $-3.81B | $-73.48M | $-3.10B | $-6.67B | $-10.98M | $-84.34M | $-133.82M | $-199.65M | $-393.97M | $-35.88M | $-25.68M | $-29.60M |
| Net Income Ratio | -7.56% | -5.20% | -130.39% | -12.67% | -4.37% | -8.64% | -9.99% | -11.00% | -597.46% | -12.02% | -523.56% | -1180.60% | -1.98% | -16.17% | -26.60% | -44.01% | -102.78% | -12.42% | -10.66% | -16.37% |
| EPS | $-0.28 | $-0.20 | $-4.92 | $-0.49 | $-0.17 | $-0.35 | $-0.40 | $-0.42 | $-23.49 | $-0.45 | $-19.22 | $-41.58 | $-0.07 | $-0.53 | $-0.86 | $-1.31 | $-3.07 | $-0.43 | $-0.34 | $-0.40 |
| EPS Diluted | $-0.28 | $-0.19 | $-4.92 | $-0.49 | $-0.17 | $-0.35 | $-0.40 | $-0.42 | $-23.49 | $-0.45 | $-19.22 | $-41.58 | $-0.07 | $-0.53 | $-0.86 | $-1.31 | $-3.07 | $-0.43 | $-0.34 | $-0.40 |
| Weighted Average Shares Outstanding | 172.77M | 170.23M | 170.23M | 167.73M | 166.06M | 165.12M | 164.17M | 162.92M | 162.17M | 161.73M | 161.38M | 160.53M | 159.94M | 159.44M | 156.06M | 152.17M | 128.30M | 83.61M | 76.51M | 73.28M |
| Weighted Average Shares Outstanding Diluted | 172.77M | 171.50M | 170.23M | 167.73M | 166.06M | 165.12M | 164.17M | 162.92M | 162.17M | 161.73M | 161.38M | 160.53M | 159.94M | 159.44M | 156.06M | 152.17M | 128.30M | 83.61M | 76.51M | 73.28M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $1.30B | $1.12B | $918.18M | $893.48M | $733.32M |
| Short Term Investments | $- | $- | $- | $2.54M | $53.24M |
| Cash and Short Term Investments | $1.30B | $1.12B | $918.18M | $896.02M | $786.57M |
| Net Receivables | $223.96M | $230.06M | $210.55M | $168.96M | $169.28M |
| Inventory | $38.14M | $29.51M | $56.34M | $73.08M | $56.50M |
| Other Current Assets | $103.49M | $105.80M | $130.31M | $87.39M | $94.52M |
| Total Current Assets | $1.66B | $1.49B | $1.32B | $1.23B | $1.06B |
| Property Plant Equipment Net | $56.58M | $72.09M | $71.47M | $74.01M | $75.20M |
| Goodwill | $283.19M | $1.07B | $1.07B | $14.50B | $14.58B |
| Intangible Assets | $1.43B | $1.68B | $1.84B | $1.91B | $2.02B |
| Goodwill and Intangible Assets | $1.71B | $2.75B | $2.91B | $16.41B | $16.60B |
| Long Term Investments | $- | $- | $-355.60M | $-467.19M | $-537.95M |
| Tax Assets | $- | $- | $355.60M | $467.19M | $537.95M |
| Other Non-Current Assets | $81.49M | $80.26M | $48.54M | $20.70M | $18.36M |
| Total Non-Current Assets | $1.85B | $2.90B | $3.03B | $16.51B | $16.70B |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $3.52B | $4.39B | $4.35B | $17.73B | $17.76B |
| Account Payables | $33.13M | $43.64M | $47.69M | $47.26M | $46.03M |
| Short Term Debt | $- | $10.75M | $13.59M | $26.00M | $54.00M |
| Tax Payables | $28.11M | $13.55M | $14.00M | $13.06M | $1.63M |
| Deferred Revenue | $79.30M | $95.66M | $90.46M | $75.57M | $52.36M |
| Other Current Liabilities | $801.00M | $257.01M | $324.49M | $169.12M | $178.64M |
| Total Current Liabilities | $941.53M | $420.62M | $399.77M | $331.01M | $332.65M |
| Long Term Debt | $1.57B | $1.58B | $1.57B | $1.28B | $1.43B |
| Deferred Revenue Non-Current | $- | $13.62M | $3.87M | $3.83M | $2.45M |
| Deferred Tax Liabilities Non-Current | $- | $49.45M | $50.94M | $75.78M | $102.10M |
| Other Non-Current Liabilities | $- | $1.08M | $64.51M | $77.27M | $103.72M |
| Total Non-Current Liabilities | $1.57B | $1.65B | $1.64B | $1.36B | $1.54B |
| Other Liabilities | $-490.37M | $- | $- | $- | $- |
| Total Liabilities | $2.03B | $2.07B | $2.04B | $1.69B | $1.87B |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $173.00K | $167.00K | $163.00K | $160.00K | $150.00K |
| Retained Earnings | $-16.23B | $-15.23B | $-15.01B | $-1.42B | $-992.66M |
| Accumulated Other Comprehensive Income Loss | $-38.39M | $-36.99M | $-42.78M | $-6.29M | $18.52M |
| Other Total Stockholders Equity | $17.76B | $17.59B | $17.36B | $17.47B | $16.86B |
| Total Stockholders Equity | $1.49B | $2.33B | $2.31B | $16.05B | $15.88B |
| Total Equity | $1.49B | $2.33B | $2.31B | $16.05B | $15.88B |
| Total Liabilities and Stockholders Equity | $3.52B | $4.39B | $4.35B | $17.73B | $17.76B |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $3.52B | $4.39B | $4.35B | $17.73B | $17.76B |
| Total Investments | $- | $-310.66M | $-355.60M | $2.54M | $53.24M |
| Total Debt | $1.58B | $1.59B | $1.57B | $1.27B | $1.47B |
| Net Debt | $286.29M | $468.60M | $655.15M | $373.96M | $731.97M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $1.30B | $1.24B | $1.16B | $1.10B | $1.12B | $1.03B | $958.70M | $888.58M | $918.18M | $899.63M | $881.16M | $836.44M | $893.48M | $823.83M | $783.72M | $720.10M | $733.32M | $1.19B | $1.31B | $507.96M |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $2.54M | $2.54M | $2.54M | $2.54M | $2.54M | $2.53M | $53.24M | $3.07M | $2.93M | $2.82M |
| Cash and Short Term Investments | $1.30B | $1.24B | $1.16B | $1.10B | $1.12B | $1.03B | $958.70M | $888.58M | $918.18M | $899.63M | $883.70M | $838.99M | $896.02M | $826.37M | $786.26M | $722.63M | $786.57M | $1.19B | $1.31B | $510.77M |
| Net Receivables | $223.96M | $223.54M | $229.96M | $227.85M | $230.06M | $205.87M | $215.18M | $215.98M | $210.55M | $201.70M | $205.43M | $191.53M | $168.96M | $178.07M | $179.44M | $178.34M | $169.28M | $85.80M | $76.90M | $70.72M |
| Inventory | $38.14M | $36.99M | $34.90M | $32.27M | $29.51M | $35.92M | $34.05M | $45.80M | $56.34M | $59.34M | $60.26M | $70.65M | $73.08M | $56.94M | $56.99M | $58.29M | $56.50M | $11.58M | $1 | $1 |
| Other Current Assets | $103.49M | $104.23M | $119.42M | $128.21M | $105.80M | $114.78M | $113.03M | $136.35M | $130.31M | $126.91M | $107.88M | $106.88M | $87.39M | $95.94M | $82.15M | $73.06M | $94.52M | $44.59M | $28.87M | $29.86M |
| Total Current Assets | $1.66B | $1.61B | $1.51B | $1.45B | $1.49B | $1.39B | $1.32B | $1.29B | $1.32B | $1.29B | $1.26B | $1.21B | $1.23B | $1.16B | $1.10B | $1.03B | $1.06B | $1.31B | $1.40B | $596.43M |
| Property Plant Equipment Net | $56.58M | $62.15M | $64.87M | $67.06M | $72.09M | $64.94M | $65.22M | $69.31M | $71.47M | $72.46M | $77.20M | $73.97M | $74.01M | $74.96M | $70.06M | $72.84M | $75.20M | $54.30M | $40.05M | $42.27M |
| Goodwill | $283.19M | $283.19M | $283.19M | $1.07B | $1.07B | $1.07B | $1.07B | $1.07B | $1.07B | $4.85B | $4.86B | $7.90B | $14.50B | $14.47B | $14.45B | $14.45B | $14.58B | $1.69B | $742.31M | $734.39M |
| Intangible Assets | $1.43B | $1.50B | $1.55B | $1.61B | $1.68B | $1.73B | $1.78B | $1.82B | $1.84B | $1.85B | $1.87B | $1.88B | $1.91B | $1.93B | $1.96B | $2.00B | $2.02B | $386.57M | $213.47M | $214.67M |
| Goodwill and Intangible Assets | $1.71B | $1.78B | $1.83B | $2.69B | $2.75B | $2.80B | $2.86B | $2.89B | $2.91B | $6.70B | $6.73B | $9.78B | $16.41B | $16.40B | $16.42B | $16.45B | $16.60B | $2.08B | $955.79M | $949.05M |
| Long Term Investments | $- | $- | $- | $- | $-310.66M | $- | $- | $- | $-355.60M | $- | $- | $- | $-467.19M | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $310.66M | $- | $- | $- | $355.60M | $- | $- | $- | $467.19M | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $81.49M | $77.91M | $116.76M | $114.21M | $80.26M | $74.45M | $72.93M | $63.99M | $48.54M | $43.66M | $37.94M | $26.63M | $-446.49M | $17.89M | $18.33M | $28.00M | $18.36M | $7.12M | $19.88M | $15.33M |
| Total Non-Current Assets | $1.85B | $1.92B | $2.01B | $2.87B | $2.90B | $2.94B | $3.00B | $3.02B | $3.03B | $6.82B | $6.85B | $9.88B | $16.51B | $16.50B | $16.51B | $16.55B | $16.70B | $2.14B | $1.02B | $1.01B |
| Other Assets | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $3.52B | $3.53B | $3.52B | $4.32B | $4.39B | $4.33B | $4.32B | $4.31B | $4.35B | $8.10B | $8.10B | $11.09B | $17.73B | $17.65B | $17.61B | $17.58B | $17.76B | $3.45B | $2.42B | $1.60B |
| Account Payables | $33.13M | $37.80M | $56.11M | $37.67M | $43.64M | $26.00M | $16.07M | $38.62M | $47.69M | $70.78M | $94.37M | $47.41M | $47.26M | $34.66M | $42.08M | $34.38M | $46.03M | $21.41M | $10.82M | $8.14M |
| Short Term Debt | $- | $561.43M | $561.44M | $10.74M | $10.75M | $10.79M | $11.92M | $24.20M | $13.59M | $22.95M | $25.06M | $25.72M | $26.00M | $25.59M | $26.61M | $11.83M | $54.00M | $20.89M | $5.76M | $5.84M |
| Tax Payables | $28.11M | $18.49M | $756.00K | $4.13M | $13.55M | $17.84M | $16.24M | $17.97M | $14.00M | $15.96M | $12.71M | $16.56M | $13.06M | $7.19M | $6.18M | $4.42M | $1.63M | $2.70M | $1.79M | $5.48M |
| Deferred Revenue | $79.30M | $88.33M | $95.43M | $101.23M | $95.66M | $99.19M | $107.39M | $95.93M | $90.46M | $90.21M | $86.25M | $83.85M | $75.57M | $72.86M | $69.29M | $70.46M | $52.36M | $46.72M | $24.81M | $17.87M |
| Other Current Liabilities | $801.00M | $225.33M | $216.99M | $235.07M | $257.01M | $248.82M | $231.78M | $204.62M | $324.49M | $211.49M | $153.09M | $133.15M | $169.12M | $161.81M | $132.06M | $139.28M | $178.64M | $122.72M | $80.37M | $59.84M |
| Total Current Liabilities | $941.53M | $931.38M | $930.73M | $388.84M | $420.62M | $402.64M | $383.39M | $381.34M | $399.77M | $411.40M | $371.48M | $306.69M | $331.01M | $302.11M | $276.23M | $260.36M | $332.65M | $200.82M | $123.55M | $97.16M |
| Long Term Debt | $1.57B | $1.03B | $1.03B | $1.58B | $1.58B | $1.57B | $1.57B | $1.58B | $1.57B | $1.58B | $1.59B | $1.58B | $1.28B | $1.26B | $1.25B | $1.39B | $1.43B | $983.81M | $976.12M | $476.65M |
| Deferred Revenue Non-Current | $- | $10.47M | $11.74M | $15.00M | $13.62M | $13.15M | $14.24M | $4.12M | $3.87M | $3.15M | $3.37M | $2.88M | $3.83M | $4.08M | $3.50M | $2.72M | $2.45M | $4.88M | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $50.85M | $50.67M | $47.47M | $49.45M | $44.25M | $48.10M | $50.61M | $50.94M | $51.74M | $55.93M | $57.52M | $75.78M | $93.82M | $81.88M | $84.88M | $102.10M | $17.90M | $18.98M | $18.85M |
| Other Non-Current Liabilities | $- | $736.00K | $1.01M | $1.02M | $1.08M | $1.69M | $1.74M | $1.75M | $64.51M | $1.63M | $1.61M | $1.45M | $77.27M | $1.33M | $1.35M | $11.79M | $103.72M | $10.93M | $5.26M | $10.24M |
| Total Non-Current Liabilities | $1.57B | $1.09B | $1.09B | $1.64B | $1.65B | $1.63B | $1.64B | $1.64B | $1.64B | $1.64B | $1.65B | $1.64B | $1.36B | $1.36B | $1.33B | $1.49B | $1.54B | $1.02B | $1.00B | $505.74M |
| Other Liabilities | $-490.37M | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $2.03B | $2.02B | $2.02B | $2.03B | $2.07B | $2.03B | $2.02B | $2.02B | $2.04B | $2.05B | $2.02B | $1.95B | $1.69B | $1.66B | $1.61B | $1.75B | $1.87B | $1.22B | $1.12B | $602.90M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $173.00K | $172.00K | $171.00K | $169.00K | $167.00K | $166.00K | $165.00K | $164.00K | $163.00K | $162.00K | $162.00K | $161.00K | $160.00K | $160.00K | $159.00K | $154.00K | $150.00K | $84.00K | $79.00K | $74.00K |
| Retained Earnings | $-16.23B | $-16.18B | $-16.15B | $-15.31B | $-15.23B | $-15.20B | $-15.14B | $-15.08B | $-15.01B | $-11.20B | $-11.12B | $-8.02B | $-1.42B | $-1.41B | $-1.33B | $-1.19B | $-992.66M | $-598.69M | $-562.81M | $-537.13M |
| Accumulated Other Comprehensive Income Loss | $-38.39M | $-37.11M | $-38.97M | $-38.63M | $-36.99M | $-41.52M | $-38.78M | $-41.00M | $-42.78M | $-49.27M | $-29.86M | $-11.42M | $-6.29M | $-1.13M | $12.29M | $5.03M | $18.52M | $-5.63M | $-21.91M | $-34.79M |
| Other Total Stockholders Equity | $17.76B | $17.73B | $17.69B | $17.64B | $17.59B | $17.54B | $17.48B | $17.41B | $17.36B | $17.30B | $17.24B | $17.18B | $17.47B | $17.40B | $17.31B | $17.02B | $16.86B | $2.84B | $1.88B | $1.57B |
| Total Stockholders Equity | $1.49B | $1.51B | $1.50B | $2.29B | $2.33B | $2.29B | $2.30B | $2.29B | $2.31B | $6.05B | $6.08B | $9.14B | $16.05B | $15.99B | $16.00B | $15.83B | $15.88B | $2.23B | $1.29B | $1.00B |
| Total Equity | $1.49B | $1.51B | $1.50B | $2.29B | $2.33B | $2.29B | $2.30B | $2.29B | $2.31B | $6.05B | $6.08B | $9.14B | $16.05B | $15.99B | $16.00B | $15.83B | $15.88B | $2.23B | $1.29B | $1.00B |
| Total Liabilities and Stockholders Equity | $3.52B | $3.53B | $3.52B | $4.32B | $4.39B | $4.33B | $4.32B | $4.31B | $4.35B | $8.10B | $8.10B | $11.09B | $17.73B | $17.65B | $17.61B | $17.58B | $17.76B | $3.45B | $2.42B | $1.60B |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $3.52B | $3.53B | $3.52B | $4.32B | $4.39B | $4.33B | $4.32B | $4.31B | $4.35B | $8.10B | $8.10B | $11.09B | $17.73B | $17.65B | $17.61B | $17.58B | $17.76B | $3.45B | $2.42B | $1.60B |
| Total Investments | $- | $- | $- | $- | $-310.66M | $- | $- | $- | $-355.60M | $- | $2.54M | $2.54M | $2.54M | $2.54M | $2.54M | $2.53M | $53.24M | $3.07M | $2.93M | $2.82M |
| Total Debt | $1.58B | $1.59B | $1.59B | $1.59B | $1.59B | $1.57B | $1.57B | $1.57B | $1.57B | $1.58B | $1.58B | $1.57B | $1.27B | $1.25B | $1.24B | $1.39B | $1.47B | $983.81M | $981.88M | $482.49M |
| Net Debt | $286.29M | $345.01M | $426.46M | $492.33M | $468.60M | $541.66M | $615.10M | $683.48M | $655.15M | $675.90M | $696.72M | $736.50M | $373.96M | $430.28M | $453.81M | $673.01M | $731.97M | $-203.49M | $-326.96M | $-25.47M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-1.00B | $-220.37M | $-13.66B | $-428.79M | $-485.14M |
| Depreciation and Amortization | $372.66M | $351.32M | $270.64M | $219.62M | $78.09M |
| Deferred Income Tax | $-1.15M | $-1.90M | $-7.84M | $41.80M | $-90.16M |
| Stock Based Compensation | $145.95M | $201.55M | $217.85M | $302.59M | $475.53M |
| Change in Working Capital | $- | $11.64M | $-60.97M | $-50.32M | $-90.48M |
| Accounts Receivables | $-375.00K | $-10.25M | $-61.64M | $-17.51M | $-21.09M |
| Inventory | $-9.75M | $24.09M | $14.80M | $-19.49M | $-24.73M |
| Accounts Payables | $-10.37M | $-4.18M | $1.88M | $1.19M | $-88.00M |
| Other Working Capital | $- | $1.99M | $-16.01M | $-14.51M | $43.34M |
| Other Non Cash Items | $777.46M | $7.78M | $13.43B | $109.10M | $58.65M |
| Net Cash Provided by Operating Activities | $293.68M | $350.02M | $189.29M | $193.99M | $-53.51M |
| Investments in Property Plant and Equipment | $-10.79M | $-156.35M | $-172.76M | $-63.93M | $-26.04M |
| Acquisitions Net | $- | $- | $- | $-78.66M | $-567.43M |
| Purchases of Investments | $- | $- | $- | $63.93M | $26.04M |
| Sales Maturities of Investments | $- | $- | $2.51M | $60.90M | $2.50M |
| Other Investing Activities | $-113.26M | $1.00K | $2.51M | $-55.22M | $-26.04M |
| Net Cash Used for Investing Activities | $-124.05M | $-156.35M | $-167.74M | $-72.98M | $-590.98M |
| Debt Repayment | $- | $- | $- | $- | $761.85M |
| Common Stock Issued | $- | $11.13M | $5.88M | $42.59M | $59.04M |
| Common Stock Repurchased | $- | $-278.00K | $- | $- | $-26.70M |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $8.31M | $10.85M | $6.50M | $40.95M | $97.29M |
| Net Cash Used Provided by Financing Activities | $8.31M | $10.85M | $6.50M | $40.95M | $859.14M |
| Effect of Forex Changes on Cash | $-3.29M | $965.00K | $-3.34M | $-1.80M | $4.32M |
| Net Change in Cash | $174.65M | $205.49M | $24.70M | $160.16M | $218.97M |
| Cash at End of Period | $1.30B | $1.12B | $918.18M | $893.48M | $733.32M |
| Cash at Beginning of Period | $1.12B | $918.18M | $893.48M | $733.32M | $514.35M |
| Operating Cash Flow | $293.68M | $350.02M | $189.29M | $193.99M | $-53.51M |
| Capital Expenditure | $-10.79M | $-156.35M | $-172.76M | $-63.93M | $-26.04M |
| Free Cash Flow | $282.89M | $193.67M | $16.53M | $130.06M | $-79.55M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-48.41M | $-33.28M | $-837.67M | $-81.89M | $-28.89M | $-57.07M | $-65.18M | $-69.23M | $-3.81B | $-73.48M | $-3.10B | $-6.67B | $-10.98M | $-84.34M | $-133.82M | $-199.65M | $-393.97M | $-35.88M | $-25.68M | $-29.60M |
| Depreciation and Amortization | $91.67M | $91.81M | $98.85M | $100.50M | $101.48M | $97.49M | $78.83M | $73.52M | $78.88M | $65.43M | $63.45M | $62.88M | $57.03M | $55.07M | $55.09M | $52.43M | $40.06M | $15.37M | $11.43M | $11.23M |
| Deferred Income Tax | $-1.76M | $-757.00K | $2.97M | $-1.60M | $4.75M | $-3.10M | $-3.20M | $-355.00K | $-1.90M | $-3.41M | $-209.00K | $-2.32M | $-49.61M | $7.59M | $-3.18M | $87.00M | $-86.06M | $-639.00K | $-637.00K | $-2.82M |
| Stock Based Compensation | $27.47M | $34.05M | $42.11M | $42.33M | $46.82M | $52.96M | $55.73M | $46.04M | $50.75M | $55.66M | $51.00M | $60.44M | $61.62M | $71.70M | $82.97M | $86.30M | $414.38M | $20.91M | $21.93M | $18.32M |
| Change in Working Capital | $10.74M | $14.44M | $-9.59M | $-51.91M | $10.87M | $11.90M | $32.05M | $-43.18M | $-36.22M | $11.29M | $47.59M | $-83.63M | $9.03M | $7.62M | $2.69M | $-69.66M | $-107.24M | $18.30M | $10.00M | $-11.55M |
| Accounts Receivables | $-4.05M | $6.65M | $-5.10M | $2.13M | $-9.56M | $6.34M | $7.01M | $-14.05M | $-16.37M | $-1.32M | $-16.11M | $-27.84M | $1.90M | $-2.83M | $-4.86M | $-11.72M | $-4.64M | $8.32M | $-7.55M | $-17.22M |
| Inventory | $-1.42M | $-2.30M | $-2.94M | $-3.09M | $5.85M | $-2.37M | $10.61M | $10.00M | $1.09M | $1.74M | $9.95M | $2.02M | $-16.83M | $-427.00K | $643.00K | $-2.88M | $-22.34M | $-19.79M | $3.23M | $19.97M |
| Accounts Payables | $-4.51M | $-18.46M | $18.48M | $-5.87M | $17.48M | $10.12M | $-22.66M | $-9.13M | $-22.19M | $-23.35M | $46.92M | $492.00K | $12.30M | $-6.37M | $7.25M | $-11.99M | $-94.58M | $4.74M | $2.35M | $-502.00K |
| Other Working Capital | $20.73M | $28.56M | $-20.03M | $-45.08M | $-2.91M | $-2.19M | $37.08M | $-30.00M | $1.26M | $34.23M | $6.82M | $-58.31M | $11.66M | $17.26M | $-349.00K | $-43.08M | $14.32M | $25.03M | $11.98M | $-13.80M |
| Other Non Cash Items | $6.18M | $3.91M | $1.02B | $251.65M | $-4.96M | $3.42M | $2.95M | $6.36M | $3.78B | $7.52M | $3.03B | $6.61B | $16.14M | $18.95M | $48.47M | $25.55M | $17.89M | $14.14M | $18.51M | $8.11M |
| Net Cash Provided by Operating Activities | $85.90M | $110.17M | $88.68M | $8.92M | $130.08M | $105.60M | $101.18M | $13.16M | $65.55M | $63.02M | $92.47M | $-31.75M | $83.21M | $76.59M | $52.22M | $-18.03M | $-114.94M | $32.20M | $35.55M | $-6.32M |
| Investments in Property Plant and Equipment | $-29.64M | $58.60M | $-27.75M | $-35.51M | $-36.51M | $-37.65M | $-36.57M | $-45.62M | $-53.89M | $-43.20M | $-44.84M | $-30.83M | $-22.92M | $-15.10M | $-12.65M | $-13.26M | $-8.65M | $-9.30M | $-5.16M | $-2.93M |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-2.72M | $-19.61M | $-415.00K | $-55.92M | $-407.77M | $-146.16M | $-4.50M | $-9.00M |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $10.90M | $- | $12.65M | $-11.14M | $11.53M | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $-2.51M | $2.51M | $- | $- | $-66.80M | $- | $10.90M | $50.00M | $2.50M | $- | $- | $- |
| Other Investing Activities | $- | $-89.75M | $-25.84M | $-34.36M | $1.00K | $-31.85M | $-34.67M | $-43.26M | $2.51M | $-750.00K | $-42.30M | $3.26M | $61.47M | $-13.89M | $-12.65M | $14.29M | $-11.53M | $-8.07M | $-4.48M | $-1.97M |
| Net Cash Used for Investing Activities | $-29.64M | $-31.15M | $-27.75M | $-35.51M | $-36.51M | $-37.65M | $-36.57M | $-45.62M | $-53.89M | $-41.45M | $-44.84M | $-27.57M | $-20.07M | $-34.71M | $-2.17M | $-16.03M | $-413.93M | $-155.46M | $-9.66M | $-11.93M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-1.18M | $-923.00K | $588.00K | $81.53M | $-2.53M | $771.87M | $- |
| Common Stock Issued | $- | $957.00K | $3.83M | $1.65M | $1.11M | $3.91M | $3.08M | $3.03M | $5.88M | $2.08M | $-313.00K | $7.26M | $25.78M | $8.14M | $8.26M | $20.56M | $54.31M | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $-278.00K | $- | $- | $- | $- | $- | $-313.00K | $- | $- | $- | $- | $- | $-26.70M | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $2.06M | $-259.00K | $3.81M | $1.75M | $-1.77M | $5.07M | $4.21M | $3.35M | $4.38M | $634.00K | $-1.33M | $2.82M | $6.62M | $1.96M | $12.29M | $21.59M | $-11.09M | $2.95M | $1.35M | $15.05M |
| Net Cash Used Provided by Financing Activities | $2.06M | $698.00K | $3.81M | $1.75M | $-1.77M | $5.07M | $4.21M | $3.35M | $4.38M | $634.00K | $-1.33M | $2.82M | $6.62M | $784.00K | $11.36M | $22.18M | $70.44M | $422.00K | $773.23M | $15.05M |
| Effect of Forex Changes on Cash | $-3.85M | $1.76M | $-292.00K | $-899.00K | $1.35M | $-1.19M | $1.30M | $-488.00K | $2.51M | $-3.74M | $-1.58M | $-538.00K | $-106.00K | $-2.56M | $2.21M | $-1.34M | $4.45M | $1.30M | $1.77M | $-3.20M |
| Net Change in Cash | $54.46M | $81.48M | $64.45M | $-25.74M | $93.15M | $71.83M | $70.12M | $-29.60M | $18.55M | $18.47M | $44.72M | $-57.04M | $69.65M | $40.10M | $63.62M | $-13.22M | $-453.98M | $-121.54M | $800.89M | $-6.40M |
| Cash at End of Period | $1.30B | $1.24B | $1.16B | $1.10B | $1.12B | $1.03B | $958.70M | $888.58M | $918.18M | $899.63M | $881.16M | $836.44M | $893.48M | $823.83M | $783.72M | $720.10M | $733.32M | $1.19B | $1.31B | $507.96M |
| Cash at Beginning of Period | $1.24B | $1.16B | $1.10B | $1.12B | $1.03B | $958.70M | $888.58M | $918.18M | $899.63M | $881.16M | $836.44M | $893.48M | $823.83M | $783.72M | $720.10M | $733.32M | $1.19B | $1.31B | $507.96M | $514.35M |
| Operating Cash Flow | $85.90M | $110.17M | $88.68M | $8.92M | $130.08M | $105.60M | $101.18M | $13.16M | $65.55M | $63.02M | $92.47M | $-31.75M | $83.21M | $76.59M | $52.22M | $-18.03M | $-114.94M | $32.20M | $35.55M | $-6.32M |
| Capital Expenditure | $-29.64M | $-31.15M | $-27.75M | $-35.51M | $-36.51M | $-37.65M | $-36.57M | $-45.62M | $-53.89M | $-43.20M | $-44.84M | $-30.83M | $-22.92M | $-15.10M | $-12.65M | $-13.26M | $-8.65M | $-9.30M | $-5.16M | $-2.93M |
| Free Cash Flow | $56.26M | $79.03M | $60.94M | $-26.59M | $93.58M | $67.95M | $64.61M | $-32.47M | $11.66M | $19.82M | $47.63M | $-62.58M | $60.29M | $61.49M | $39.56M | $-31.29M | $-123.59M | $22.90M | $30.39M | $-9.25M |
Teladoc Health Dividends
Explore Teladoc Health's dividend history, including dividend yield, payout ratio, and historical payments.
Teladoc Health News
Read the latest news about Teladoc Health, including recent articles, headlines, and updates.
Teladoc stock forms a giant double bottom: will it rise after earnings?
Teladoc Health stock price continues to crash and is hovering at its lowest level on record ahead of its first-quarter earnings. It was trading at $7.16 on Monday, meaning that it has crashed by 21% this year and 46% in the last 12 months.
Teladoc: Back In The Doldrums After Another Tough Year (Rating Downgrade)
Teladoc Health, Inc.'s stock has declined significantly, from a high of $14 per share in February to $7 per share, with ongoing financial struggles and underperformance in key segments. The company reported a net loss of $1 billion in 2024, with declining revenues in its BetterHelp segment and minimal growth in Integrated Care. Despite efforts to cut costs and new initiatives like the Catapult Health acquisition and a partnership with Eli Lilly, Teladoc's value proposition remains unclear.
2 Beaten-Down Stocks to Avoid in the Tariff-Fueled Correction
With equity markets reeling due to President Donald Trump's tariffs, many investors are taking this opportunity to buy shares of top companies on the dip. It's a great strategy, but it's essential to avoid those companies that only look undervalued but actually aren't.
Teladoc Health Introduces Next Generation Cardiometabolic Health Program
PURCHASE, NY, April 08, 2025 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today introduced its next generation Cardiometabolic Health Program to improve population health and prevent the progression of diabetes, hypertension and obesity. Building on the company's industry-leading chronic condition management programs, the new offering is designed to support optimal cardiometabolic health for all populations.
Should Investors Buy These 2 Beaten-Down Artificial Intelligence (AI) Healthcare Stocks?
Artificial intelligence (AI) is changing the world. Corporations are racing to establish themselves as leaders in the field, while investors want to cash in by putting their hard-earned money into the most promising AI companies.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teladoc Health, Inc. - TDOC
NEW YORK, NY / ACCESS Newswire / March 19, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Teladoc Health, Inc. ("Teladoc" or the "Company") (NYSE:TDOC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Does Teladoc's $65 Million Acquisition of Catapult Health Make the Stock a Buy?
Telemedicine specialist Teladoc Health (TDOC 1.53%) has been a terrible investment over the past three years. Once the company's pandemic-fueled business boom cooled down, its revenue and visit growth slowed down considerably while it remained unprofitable.
Carrum Health Selected by Teladoc Health as Centers of Excellence Partner
The partnership enables Teladoc Health's employer clients and members more streamlined and fully integrated access to Carrum's value-based Centers of Excellence network for specialty care SAN FRANCISCO , March 13, 2025 /PRNewswire/ -- Carrum Health, the leader in value-based Centers of Excellence (COE) for specialty care, today announced a strategic partnership with Teladoc Health (NYSE: TDOC), the global leader in virtual care. The new arrangement will allow Teladoc Health's providers to seamlessly refer eligible members needing specialty care into Carrum's nationwide network of rigorously vetted, high quality providers.
Cylinder joins Teladoc Health's Connected Care Program to expand access to virtual digestive care
CHICAGO, March 12, 2025 (GLOBE NEWSWIRE) -- Cylinder , the leading virtual digestive health provider, today announced its partnership with Teladoc Health (NYSE: TDOC), the global leader in virtual care, to expand access to high-quality, personalized gastrointestinal care. Through this collaboration, Teladoc Health's health plan and employer customers can easily provide members access to Cylinder's evidence-based digestive health platform, through streamlined administrative services and integration enablement.
Teladoc Health Expands Connected Care Partnerships
New digital health partners in specialty care, digestive health, fertility, and family building available for Teladoc Health care team referral on the company's Prism care platform New digital health partners in specialty care, digestive health, fertility, and family building available for Teladoc Health care team referral on the company's Prism care platform
Teladoc Health Partners With Eli Liily's LillyDirect to Expand Access to Zepbound For Weight Loss
Telemedicine operator Teladoc Health Inc TDOC has entered a pharmacy integration agreement with Eli Lilly And Co's LLY LillyDirect, a direct-to-consumer pharmacy partner, to streamline access to Zepbound (tirzepatide) for members of Teladoc's Comprehensive Weight Care Program.
Telehealth firms Teladoc, LifeMD tie up with Eli Lilly's pharmacy partner to offer Zepbound
Telehealth firms Teladoc Health and LifeMD said on Thursday they have signed an agreement with Eli Lilly's direct-to-consumer website LillyDirect pharmacy partner, Gifthealth, to offer patients the weight-loss drug, Zepbound.
Teladoc Health Adds GLP-1 Self-Pay Option to Comprehensive Weight Care
Pharmacy Integration with Gifthealth to Extend Seamless Support for FDA-Approved Medication to Obesity Program Members Without GLP-1 Coverage Pharmacy Integration with Gifthealth to Extend Seamless Support for FDA-Approved Medication to Obesity Program Members Without GLP-1 Coverage
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for TDOC.